MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
Launched by NORTHWESTERN UNIVERSITY · Jun 15, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The MAGIC trial is studying how two tests, a special type of MRI and a genomic test called the Genomic Prostate Score (GPS), can help men with low-risk prostate cancer make better treatment decisions. The goal is to see if these tests can help doctors determine which patients are safe to monitor closely and which ones may need more immediate treatment. This trial specifically aims to gather data on Black men and those treated at public hospitals, focusing on how well these tests can improve patient follow-up and safety during active surveillance, which is a way to monitor cancer without immediate treatment.
To participate in this study, men aged 40 to 76 who have recently been diagnosed with very low to intermediate-risk prostate cancer may be eligible, provided they are willing to consider active surveillance as a treatment option. Participants can expect to undergo both the MRI and GPS tests to help identify their risk levels over an 18-month period. Additionally, they will share their views on the importance of these tests and other factors influencing their treatment choices. This information will help doctors and patients make informed decisions regarding prostate cancer management while reducing the number of unnecessary biopsies and procedures.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Participants must have NCCN very low to favorable intermediate risk prostate cancer.
- • Participants must be diagnosed within 3 months prior to study enrollment.
- • Participants must be male, age 40-76 years old.
- • Participants must be willing to consider active surveillance for treatment.
- Exclusion Criteria:
- • Participants with less than 10 years life expectancy.
- • Participants unable to complete standardized surveys.
- • Participants with no access to the rectum for a transrectal ultrasound.
- • Participants with a contraindication to magnetic resonance imaging (MRI).
About Northwestern University
Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Chicago, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials